Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Levels of VEGF-A, VEGF-C, sVEGFR-1, and sVEGFR-2 in tumor tissue and serum of patients with rare endometrial carcinomas.

Mark A. Rogozin, Anna Petrovna Menshenina, Elena M. Frantsiyants et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17628

e17628 Background: Uterine serous carcinoma (USC) and clear cell carcinoma (CCC) are rare and clinically aggressive forms...

Telisotuzumab adizutecan (Temab-A) plus osimertinib (osi) as 1L treatment for unresectable/metastatic NSCLC.

Yasushi Goto, Christina S. Baik, Federico Cappuzzo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8663

TPS8663 Background: Most patients (pts) with EGFR-mutated (Mut) NSCLC and 1L osi treatment will eventually develop resista...

First-in-human phase 1 evaluation of the world’s first tri-specific SIRPα–PD-1–TGF-β Fc fusion protein HCB301 in advanced solid tumors.

Ji Zhu, William Jeffery Edenfield, Hongyan Tong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14570

e14570 Background: Tumor immune resistance arises from coordinated suppression of innate immunity, adaptive T-cell activit...

Molecular grouping of NUT carcinoma within a cancer family context.

Samuel Shenoi, Cathy Charles, Iris Yeong- Fung Sheng Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18053

e18053 Background: NUT carcinomas are characterized by ectopic expression of nuclear protein in testis (NUT). These rare s...

Patient-reported outcomes based on voice-based artificial intelligence (VAAIPRO): A fast and innovative QOL data collection application.

Dinesh Pendharkar, Dhruv Mehra, Ashish Tripathy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13658

e13658 Background: Health-related quality of life (QoL) is a key endpoint in oncology, typically assessed using validated...

Genetic testing uptake through an enhanced oncology nurse–led intervention in patients with solid tumors (GENESIS): A pilot study.

Ranjan Pathak, Edward A. Roualdes, Rachel Garibaldi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1677

TPS1677 Background: Identification of pathogenic germline variants (PGV) in patients with solid tumors is critical for dir...

Application of Bayesian methodology in radiopharmaceutical therapies dose optimization.

Hui Wang, Juan Li, Xiaoyue Zhao Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15152

e15152 Background: Radiopharmaceutical therapies (RPTs) exhibit complex dose-response relationships due to inter-patient h...

Epidemiology of early-onset colorectal cancer in the WHO Eastern Mediterranean Region: Regional and global comparisons.

Fares A. Qtaishat, Jehad A. Yasin, Muaath Alsufi et al. Jun 01, 2026 pp. 3660-3660 10.1200/jco.2026.44.16_suppl.3660

3660 Background: Early onset colorectal cancer (EO-CRC) is increasing globally, yet studies from the WHO Eastern Mediterra...

The impact of re-adoption of open radical hysterectomy on postoperative outcomes in the United States: An interrupted time series analysis.

Alex Ede Rosenthal Powers, William Manning, Christina Onyebuchi et al. Jun 01, 2026 pp. 5538-5538 10.1200/jco.2026.44.16_suppl.5538

5538 Background: The Laparoscopic Approach to Cervical Cancer (LACC) trial, published in 2018, demonstrated inferior disea...

Association of Schwann cells with immune-cold tumor microenvironment in triple-negative breast cancer.

Kei Kawashima, Masanori Oshi, Akimitsu Yamada et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12592

e12592 Background: Although intratumoral nerves have recently been recognized as a critical regulator of tumor biology, it...

Prevalence of depression and associated factors among patients with advanced cancer undergoing comprehensive genomic profiling testing in Japan.

Ayumu Matsuoka, Takafumi Koyama, Shunsuke Kato et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24108

e24108 Background: Comprehensive genomic profiling (CGP) testing is increasingly used in patients with advanced cancer to...

KEYNOTE-811: 6-year median follow-up of pembrolizumab plus trastuzumab and chemotherapy for previously untreated advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Akihito Kawazoe, Sun Young Rha, Yuxian Bai et al. Jun 01, 2026 pp. 4040-4040 10.1200/jco.2026.44.16_suppl.4040

4040 Background: At the final analysis of the phase 3 KEYNOTE-811 trial (NCT03615326), first-line (1L) pembrolizumab (pemb...

Association of GLP-1 receptor agonist use with mortality and hospitalization in women with breast cancer and type 2 diabetes: A propensity score–matched cohort study.

Ahmad Habbas, Samer Jumean, Ahmad Al-Riyalat et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12731

e12731 Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in patients with type 2 dia...

PRIME-ROSE: A blueprint for implementing precision cancer medicine in Europe.

Gro Live Fagereng, Henk van der Pol, Tina Kringelbach et al. Jun 01, 2026 pp. 11086-11086 10.1200/jco.2026.44.16_suppl.11086

11086 Background: Precision Cancer Medicine (PCM) is limited by increasingly small patient subgroups defined by tumor type...

Real-world survival and safety outcomes of tarlatamab in patients with extensive stage small cell lung cancer.

Sangam Sangam, Sneha Singh, Anuja Vidyadhar Abhyankar Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20168

e20168 Background: Tarlatamab, a DLL-3 targeted bispecific T cell engager targeting Delta-Like ligand 3 has shown promisin...

SGLT2 inhibitor use and long-term outcomes in anthracycline-treated breast cancer: A real-world retrospective cohort study.

Lay She Ng, Wern Lynn NG, Yone Phar Lin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12707

e12707 Background: Anthracycline-based chemotherapy remains a cornerstone of breast cancer treatment but is limited by dos...

Clinicogenomic characterization of MUC16 and MUC17 in small cell lung cancer.

Nina Cheranda, Neha Puttagunta, Divya Chukkalore et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20165

e20165 Background: Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapies and poor survival. Tra...

Whole slide imaging–based prediction of immunohistochemistry markers and surgical pathological features.

Yusuf Sadek, Jiaxiang Sun, Yiming Zhu et al. Jun 01, 2026 pp. 6022-6022 10.1200/jco.2026.44.16_suppl.6022

6022 Background: Immunohistochemistry (IHC) marker testing and identification of pathological features are essential tasks...

Sintilimab plus anlotinib and chemotherapy as first-line treatment for advanced malignant pleural mesothelioma (SACH-MPM): A prospective, single-arm, phase II trial.

Yiyi Huang, Xinyu Wu, Xiaohui Ren et al. Jun 01, 2026 pp. 8050-8050 10.1200/jco.2026.44.16_suppl.8050

8050 Background: Standard first-line treatments for advanced malignant pleural mesothelioma (MPM) include platinum-pemetre...

A phase 2 pivotal study of savolitinib in patients with <i>MET</i> -amplified gastric cancer or gastroesophageal junction adenocarcinomas.

Zhi Peng, Tianshu Liu, Jufeng Wang et al. Jun 01, 2026 pp. 4011-4011 10.1200/jco.2026.44.16_suppl.4011

4011 Background: MET amplification is a poor prognosis for survival in patients (pts) with gastric cancer (GC) or gastroes...

Multimodal profiling of STIC lesions to identify precursor states with genomic features of high grade serous ovarian cancer.

Duaa Al-Rawi Jun 01, 2026 pp. 10581-10581 10.1200/jco.2026.44.16_suppl.10581

10581 Background: High-grade serous ovarian cancer (HGSC) is a lethal gynecologic malignancy characterized by near-univers...

Changes in metastatic breast cancer (MBC) bone lesions and SREs/fractures via a single intratumoral injection for a first-of-its-kind drug: Preliminary phase 2a results.

Manraj Heran, Bryan Samuel Margulies, Joe C. Loy et al. Jun 01, 2026 pp. 589-589 10.1200/jco.2026.44.16_suppl.589

589 Background: Lytic bone metastases develop in ~70% of breast cancer patients that lead to pain, functional decline, and...

Early-onset pancreatic cancer in the United States (1991–2021): Temporal trends, geographic variation, and gender disparities.

Adit Patel, Jahnavi Chaudhari, Hetul Chaudhari et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16444

e16444 Background: Early-onset pancreatic cancer (EOPC), defined as pancreatic cancer diagnosed before the age of 50, rema...

Health-related social needs screening in community oncology settings: Results from the WF-2303CD context assessment of NCORP clinics.

Emily Ruth Haines, Sarah Birken, Laura Clark et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23181

e23181 Background: Health-related social needs (HRSN; i.e., health-harming conditions like food insecurity and housing ins...

Trends and disparities in appendiceal cancer mortality in the United States from 1999 to 2023.

Anoud Khan, Aryan Tareen, Saqib Raza Khan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15678

e15678 Background: Appendiceal cancer (AC), once rare, is now recognized as a complex disease with rising mortality. At di...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page